HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CDK10
cyclin dependent kinase 10
Chromosome 16 Β· 16q24.3
NCBI Gene: 8558Ensembl: ENSG00000185324.23HGNC: HGNC:1770UniProt: B7Z537
61PubMed Papers
21Diseases
4Drugs
29Pathogenic Variants
FUNCTIONAL ROLE
Kinase
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
negative regulation of cilium assemblyprotein serine/threonine kinase activitypeptidyl-threonine phosphorylationnucleusAl Kaissi syndromeneurodegenerative diseasegenetic disorderIntellectual disability
✦AI Summary

CDK10 is a cyclin-dependent kinase that functions as both a tumor suppressor and regulator of cellular processes critical for development and immunity. The kinase phosphorylates multiple substrates including ETS2, promoting its proteasomal degradation 1, and PKN2, which negatively regulates ciliogenesis through RhoA signaling 1. CDK10 acts as a tumor suppressor in several cancer types, with downregulation observed in biliary tract cancers 2 and nasopharyngeal carcinomas, where promoter hypermethylation silences expression 3. However, CDK10 also suppresses antitumor immunity by phosphorylating DNMT1 and RAP80, reducing double-stranded RNA and R-loop accumulation, thereby inhibiting MDA5 and cGAS-mediated innate immune activation 4. Loss-of-function mutations cause severe developmental disorders characterized by growth retardation, spine malformations, and developmental delays 5. CDK10 expression is elevated in Alzheimer's disease brain tissue, particularly in the cerebellum 6. The protein exists as multiple isoforms with different subcellular localizations and shows tissue-specific expression patterns 7. These diverse functions highlight CDK10's complex roles in development, cancer biology, and immune regulation.

Sources cited
1
CDK10 phosphorylates ETS2 promoting its degradation and PKN2 regulating ciliogenesis through RhoA signaling
PMID: 28178678
2
CDK10 functions as tumor suppressor in biliary tract cancer with downregulated expression
PMID: 22209942
3
CDK10 is silenced by promoter hypermethylation in nasopharyngeal carcinomas
PMID: 23740091
4
CDK10 suppresses antitumor immunity by phosphorylating DNMT1 and RAP80, inhibiting MDA5 and cGAS pathways
PMID: 41507536
5
Loss-of-function CDK10 mutations cause severe growth retardation, spine malformations, and developmental delays
PMID: 28886341
6
CDK10 expression is elevated in Alzheimer's disease brain tissue, particularly cerebellum
PMID: 36988771
7
CDK10 exists as multiple isoforms with different subcellular localizations and tissue-specific expression
PMID: 11006117
Disease Associationsβ“˜21
Al Kaissi syndromeOpen Targets
0.73Strong
neurodegenerative diseaseOpen Targets
0.53Moderate
genetic disorderOpen Targets
0.45Moderate
Intellectual disabilityOpen Targets
0.37Weak
Global developmental delayOpen Targets
0.34Weak
Abnormal brain morphologyOpen Targets
0.33Weak
melanomaOpen Targets
0.14Weak
hair colorOpen Targets
0.14Weak
skin neoplasmOpen Targets
0.12Weak
neoplasmOpen Targets
0.12Weak
small cell lung carcinomaOpen Targets
0.10Suggestive
skin cancerOpen Targets
0.08Suggestive
VitiligoOpen Targets
0.07Suggestive
chronic lymphocytic leukemiaOpen Targets
0.07Suggestive
Mantle cell lymphomaOpen Targets
0.07Suggestive
actinic keratosisOpen Targets
0.07Suggestive
hypertensionOpen Targets
0.07Suggestive
non-small cell lung carcinomaOpen Targets
0.06Suggestive
mathematical abilityOpen Targets
0.06Suggestive
multiple myelomaOpen Targets
0.06Suggestive
Al Kaissi syndromeUniProt
Pathogenic Variants29
NM_052988.5(CDK10):c.729del (p.Glu244fs)Pathogenic
not provided|Al Kaissi syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 244
NM_052988.5(CDK10):c.609-1G>APathogenic
not provided|Al Kaissi syndrome
β˜…β˜…β˜†β˜†2025
NM_052988.5(CDK10):c.520_521del (p.Lys174fs)Pathogenic
not provided|Al Kaissi syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 174
NM_052988.5(CDK10):c.870_871del (p.Trp291fs)Pathogenic
Al Kaissi syndrome|Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 291
NM_052988.5(CDK10):c.87+5G>APathogenic
Al Kaissi syndrome|not provided
β˜…β˜…β˜†β˜†2024
NM_052988.5(CDK10):c.608+1G>APathogenic
Al Kaissi syndrome|not provided
β˜…β˜…β˜†β˜†2023
NM_052988.5(CDK10):c.664_665del (p.Met222fs)Pathogenic
not provided|Al Kaissi syndrome
β˜…β˜…β˜†β˜†2019β†’ Residue 222
NM_052988.5(CDK10):c.24C>A (p.Cys8Ter)Pathogenic
Al Kaissi syndrome|not provided
β˜…β˜…β˜†β˜†β†’ Residue 8
NM_052988.5(CDK10):c.139del (p.Glu47fs)Likely pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 47
NM_052988.5(CDK10):c.846C>G (p.Tyr282Ter)Likely pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 282
NM_052988.5(CDK10):c.613C>T (p.Arg205Ter)Likely pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†2023β†’ Residue 205
NM_052988.5(CDK10):c.716_728del (p.Leu239fs)Pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†2022β†’ Residue 239
NM_052988.5(CDK10):c.299_300dup (p.Leu101fs)Likely pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†2022β†’ Residue 101
NM_052988.5(CDK10):c.202A>T (p.Lys68Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2021β†’ Residue 68
NC_000016.10:g.(?_89685346)_(89692516_?)delPathogenic
not provided
β˜…β˜†β˜†β˜†2019
NM_052988.5(CDK10):c.550_556del (p.Leu184fs)Likely pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†2018β†’ Residue 184
NM_052988.5(CDK10):c.178del (p.Gln60fs)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2017β†’ Residue 60
NM_052988.5(CDK10):c.503del (p.Asn168fs)Pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†β†’ Residue 168
NM_052988.5(CDK10):c.161-2A>GLikely pathogenic
Al Kaissi syndrome
β˜…β˜†β˜†β˜†
NM_052988.5(CDK10):c.872G>A (p.Trp291Ter)Pathogenic
Global developmental delay
β˜…β˜†β˜†β˜†β†’ Residue 291
View on ClinVar β†—
Drug Targets4
AT-7519Phase II
Cyclin-dependent kinase inhibitor
chronic lymphocytic leukemia
AZD-5438Phase I
Cyclin-dependent kinase inhibitor
PHA-793887Phase I
Cyclin-dependent kinase inhibitor
RONICICLIBPhase II
Cyclin-dependent kinase inhibitor
small cell lung carcinoma
Related Genes
ETS2Protein interaction95%CCNQProtein interaction84%ZNF276Protein interaction79%CCNL2Protein interaction79%SPG7Protein interaction77%GALNSProtein interaction74%
Tissue Expression6 tissues
Liver
100%
Ovary
45%
Lung
39%
Bone Marrow
38%
Heart
17%
Brain
7%
Gene Interaction Network
Click a node to explore
CDK10ETS2CCNQZNF276CCNL2SPG7GALNS
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q15131
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
1.34LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF1.07 [0.86–1.34]
RankingsWhere CDK10 stands among ~20K protein-coding genes
  • #7,540of 20,598
    Most Researched61
  • #1,851of 5,498
    Most Pathogenic Variants29
  • #14,071of 17,882
    Most Constrained (LOEUF)1.34
Genes detectedCDK10
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
CDK10 suppresses nucleic acid sensors-mediated antitumor immunity.
PMID: 41507536
Nat Cancer Β· 2026
1.00
2
Human CDK10 gene isoforms.
PMID: 11006117
Biochem Biophys Res Commun Β· 2000
0.90
3
CDK10, CDK11, FOXO1, and FOXO3 Gene Expression in Alzheimer's Disease Encephalic Samples.
PMID: 36988771
Cell Mol Neurobiol Β· 2023
0.80
4
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
PMID: 22209942
Oncol Rep Β· 2012
0.70
5
Biomarker and genomic analyses reveal molecular signatures of non-cardioembolic ischemic stroke.
PMID: 37248226
Signal Transduct Target Ther Β· 2023
0.60